Chickenpox Vaccine clinical trials
Also written Zostavax and VARIVAX®.
Its developmentBy 6 companies, company by company43 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.How each study uses Chickenpox Vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Chickenpox Vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Mar 1995 · Varivax · BLA 103552 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
76 studies that test it; most in 2015 (7)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 1 |
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 6 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 7 |
| 2016 | 6 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 5 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 44 · Other 32
Merck Sharp & Dohme LLC (20) · Sinovac (Dalian) Vaccine Technology Co., Ltd. (11) · Sanofi Pasteur, a Sanofi Company (4) · GlaxoSmithKline (4) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · University of Colorado, Denver (3) · Seoul National University Hospital (2) · Changchun Keygen Biological Products Co., Ltd. (2)
Often tested with
Tested in the same studies.
Measles-Mumps-Rubella Vaccine (3) · Shingrix (2) · RotaTeq (2) · Hepatitis B Vaccines (2) · Heptavalent Pneumococcal Conjugate Vaccine (2) · Hepatitis A Vaccines (2) · Fludarabine (1) · Cyclophosphamide (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Chickenpox Vaccine is the comparator. A study of two new drugs counts under both.
- 1MG1111 · GC Biopharma Corp · next primary completion Aug 2027
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Chickenpox Vaccine, phase 3 first.
- Feb 2027SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 YearsPhase 3 · SK Bioscience Co., Ltd.
Studies
Open first, then newest update. How each study uses Chickenpox Vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 76
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 YearsRecruitingPhase 3SK Bioscience Co., Ltd.NCT07415252Written as Varivax®How we know
- Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese ChildrenNot yet recruitingPhase 3Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT07473427Written as Varicella VaccineHow we know
- An Immunity Persistence Study of Live Attenuated Varicella VaccineEnrolling by invitationPhase 4Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT05095701Written as Investigational Live Attenuated Varicella VaccineHow we know
- An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella VaccineEnrolling by invitationPhase 4Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT06484686Written as Live Attenuated Varicella VaccineHow we know
- Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation RecipientsRecruitingPhase 2/3University Hospital, GenevaNCT00492739Written as Vaccination with VZV vaccineHow we know
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and ToddlersTerminatedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT06397768Written as Varicella virus vaccineHow we know
- ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ TumorsTerminatedPhase 4Louis Stokes VA Medical CenterNCT02444936Written as ZOSTAVAXHow we know
- The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using AbataceptCompletedPhase 2Kevin WinthropNCT03604406Written as Varicella Zoster VaccineHow we know
- iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and NeuroblastomaActive, not recruitingPhase 1Baylor College of MedicineNCT01953900Written as VZV vaccineHow we know
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT04398706Written as Varicella Virus Vaccine LiveHow we know
- Study on Booster Immunization With Varicella Vaccine at Different IntervalsCompletedPhase 4Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT06994052Written as Varicella vaccineHow we know
- Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)CompletedPhase 4Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT06987942Written as Varicella vaccine+TIVHow we know
- Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the PhilippinesCompletedPhase 3Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT06314724Written as Varicella VaccineHow we know
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03691610Written as Varicella Virus Vaccine LiveHow we know
- T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020CompletedPhase 4Stanford UniversityNCT01911065Written as Zostavax™How we know
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella VaccineActive, not recruitingPhase 3China National Biotec Group Company LimitedNCT05669625Written as Investigational live attenuated varicella vaccineHow we know
- Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster VirusStatus unknownPhase 4Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT05460429Written as Live attenuated varicella vaccineHow we know
- Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui ProvinceStatus unknownPhase 4Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT05470855Written as Live attenuated varicella vaccineHow we know
- Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney TransplantationCompletedPhase 4University of AlbertaNCT00940940Written as Zostavax (Live attenuated herpes zoster vaccine)How we know
- An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster ImmunizationCompletedPhase 3Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT05150392Written as Investigational live attenuated varicella vaccineHow we know
See all 76 studies that test Chickenpox Vaccine →
Given beside what is tested · 18 — Chickenpox Vaccine is usual care or a partner of the new treatment
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT03621670Written as VarivaxHow we know
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3Sanofi Pasteur, a Sanofi CompanyNCT06736041Written as VarivaxHow we know
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824194Written as VarivaxHow we know
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06975878Written as Varivax vaccineHow we know
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824181Written as VarivaxHow we know
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the USCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03537508Written as Varicella vaccineHow we know
- Persistence of Protection by ShingrixCompletedPhase 4University of Colorado, DenverNCT04169009Written as ZostavaxHow we know
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)CompletedPhase 3Merck Sharp & Dohme LLCNCT03893448Written as VARIVAX™How we know
- Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)CompletedPhase 3Merck Sharp & Dohme LLCNCT04016714Written as VARIVAX™How we know
- A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)CompletedPhase 3Merck Sharp & Dohme LLCNCT03620162Written as VARIVAX™How we know
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and ToddlersCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT01049035Written as Varicella Virus Vaccine LiveHow we know
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of AgeCompletedPhase 3GlaxoSmithKlineNCT02184572Written as VarivaxHow we know
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifeCompletedPhase 3GlaxoSmithKlineNCT01681992Written as VarivaxHow we know
- Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of AgeCompletedPhase 2GlaxoSmithKlineNCT00861744Written as Varivax®How we know
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of AgeCompletedPhase 3GlaxoSmithKlineNCT01702428Written as VarivaxHow we know
- Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate VaccinesCompletedPhase 2GlaxoSmithKlineNCT00134719Written as Varivax®How we know
- ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00535730Written as Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™How we know
- Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.CompletedPhase 3GlaxoSmithKlineNCT00345683Written as VarivaxHow we know
As the comparator · 20 — what is tested is compared with Chickenpox Vaccine
- A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 YearsRecruitingPhase 3GC Biopharma CorpNCT07054099Written as VARIVAX™How we know
- Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP VaccineNot yet recruitingPhase 4Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT06891872Written as Varicella VaccineHow we know
- Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella VaccinationRecruitingPhase 2Green Cross CorporationNCT05422508Written as VARIVAXHow we know
- Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and OlderActive, not recruitingPhase 1/2Ab&B Bio-tech Co., Ltd.JSNCT06851832Written as Zoster Vaccine, LiveHow we know
- Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CVCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01190228Written as Varicella VaccineHow we know
- A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.CompletedPhase 3GlaxoSmithKlineNCT02570126Written as Varilrix™How we know
- Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of AgeCompletedPhase 3SK Bioscience Co., Ltd.NCT03114943Written as VarivaxHow we know
- An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in ChildrenCompletedPhase 3GlaxoSmithKlineNCT01439360Written as VarilrixHow we know
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTMCompletedPhase 3GlaxoSmithKlineNCT00969436Written as Varilrix™How we know
- Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy AdultsCompletedPhase 1Green Cross CorporationNCT02367638Written as VARIVAXHow we know
- Safety Study of NBP608 in Healthy Adult VolunteersCompletedPhase 1SK Chemicals Co., Ltd.NCT03121638Written as VARIVAXHow we know
- Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and OverCompletedPhase 3SK Chemicals Co., Ltd.NCT03120364Written as ZostavaxHow we know
- Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and OverCompletedPhase 2/3SK Chemicals Co., Ltd.NCT03116594Written as ZostavaxHow we know
- The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of AgeCompletedPhase 2SK Chemicals Co., Ltd.NCT03114982Written as VarivaxHow we know
- A Study of ProQuad™ in Healthy Children in Korea (V221-023)TerminatedPhase 3Merck Sharp & Dohme LLCNCT00839917Written as M-M-R™ II and Varivax™How we know
- Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00985153Written as Comparator: VarivaxHow we know
- A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)CompletedPhase 1Merck Sharp & Dohme LLCNCT00886613Written as Comparator: Zostavax™How we know
- ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00975507Written as Comparator: VarivaxHow we know
- Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric VaccinesCompletedPhase 3Merck Sharp & Dohme LLCNCT00984295Written as Comparator: VarivaxHow we know
- A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)CompletedPhase 3Merck Sharp & Dohme LLCNCT00985166Written as Comparator: VarivaxHow we know